Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

How Sweet It Isn’t: Genentech Investors Want Higher Roche Bid

This article was originally published in The Pink Sheet Daily

Executive Summary

New survey suggests Genentech’s minority shareholders won’t tender at the $86.50 price.
Advertisement

Related Content

Roche Checks Wallet As Important Avastin Trial Flops
Roche Checks Wallet As Important Avastin Trial Flops
The Genentech Sales Pitch: Higher Values R Us
No Surprise: Genentech Urges Shareholders Not To Tender Shares
Merger Gamesmanship: Genentech Had Countered First Roche Bid With 26% Higher Asking Price
Roche’s Weak Earnings Add Fuel To Merger Fire
For Roche and Genentech, What’s An Agreement Between Friends?
Roche Ups Negotiating Ante With Hostile Bid For Genentech
Roche Ups Negotiating Ante With Hostile Bid For Genentech
Roche/Genentech: A Case Study For Future Hostile Offers

Topics

Advertisement
UsernamePublicRestriction

Register

PS068990

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel